Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2015 Feb 2;14(4):1035–1047. doi: 10.1158/1535-7163.MCT-14-0800

Figure 5. AZD1480 inhibits tumor-associated integrin αvβ3 expression and MMP activity.

Figure 5

The tumor associated integrin αvβ3 expression and MMP activity was detected by combined anatomic imaging (MRI) and fluorescent molecular tomography (FMT). Tumor-bearing mice were treated with vehicle or AZD1480 (n=5/group) for 4 weeks and imaged weekly by MRI to monitor tumor growth and FMT to monitor integrin αvβ3 probe binding and MMP probe activation. A) Representative MRI images, IntegriSense probe binding and MMPSense probe activation in ovarian tumors in vehicle- and AZD1480-treated mice. Quantification of tumor volume by MRI (B), and IntegriSense probe retention (C) and MMP probe activation (D) by FMT. (*p<0.05, **p<0.01).